Durable tracking anti-SARS-CoV-2 antibodies in cancer patients recovered from COVID-19

Abstract Cancer patients are more susceptible to SARS-CoV-2 infection and generally have higher mortality rate. Anti-SARS-CoV-2 IgG is an important consideration for the patients in this COVID-19 pandemic. Recent researches suggested the rapid decay of anti-SARS-CoV-2 antibodies in the general popul...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yongsheng Huang, Jing Yu, Dan Li, Kai He, Wenyang Liu, Lin Wang, Yeshan Chen, Conghua Xie, Xiaowei Wu
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/2bf4547a9fc44aaab5e7dcaaaeccfa1a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2bf4547a9fc44aaab5e7dcaaaeccfa1a
record_format	dspace
spelling	oai:doaj.org-article:2bf4547a9fc44aaab5e7dcaaaeccfa1a2021-12-02T15:29:03ZDurable tracking anti-SARS-CoV-2 antibodies in cancer patients recovered from COVID-1910.1038/s41598-021-96195-w2045-2322https://doaj.org/article/2bf4547a9fc44aaab5e7dcaaaeccfa1a2021-08-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-96195-whttps://doaj.org/toc/2045-2322Abstract Cancer patients are more susceptible to SARS-CoV-2 infection and generally have higher mortality rate. Anti-SARS-CoV-2 IgG is an important consideration for the patients in this COVID-19 pandemic. Recent researches suggested the rapid decay of anti-SARS-CoV-2 antibodies in the general population, but the decline rate of the antibodies in cancer patients was unknown. In this observational study, we reported the clinical features of the 53 cancer patients infected by SARS-CoV-2 from Wuhan, China and tracked the presence of anti-SARS-CoV-2 antibodies in the patients for more than 12 months. We found the duration (days) of anti-SARS-CoV-2 IgG in the patients was significant longer in chemotherapy (mean: 175; range: 75 to 315) and radiotherapy groups (mean: 168; range: 85 to 265) than in non-chemo- or radio-therapy group (mean: 58; range: 21 to 123) after their recovery from COVID-19. We also used single-cell RNA sequencing to track the immunologic changes in a representative patient recovered from COVID-19 and found that CD8 + effective T cells, memory B cells and plasma cells were persistently activated in the patient undergoing chemotherapy. Together, our findings show that chemotherapy and radiotherapy might be beneficial to extend the duration of anti-SARS-CoV-2 IgG.Yongsheng HuangJing YuDan LiKai HeWenyang LiuLin WangYeshan ChenConghua XieXiaowei WuNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-6 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Yongsheng Huang Jing Yu Dan Li Kai He Wenyang Liu Lin Wang Yeshan Chen Conghua Xie Xiaowei Wu Durable tracking anti-SARS-CoV-2 antibodies in cancer patients recovered from COVID-19
description	Abstract Cancer patients are more susceptible to SARS-CoV-2 infection and generally have higher mortality rate. Anti-SARS-CoV-2 IgG is an important consideration for the patients in this COVID-19 pandemic. Recent researches suggested the rapid decay of anti-SARS-CoV-2 antibodies in the general population, but the decline rate of the antibodies in cancer patients was unknown. In this observational study, we reported the clinical features of the 53 cancer patients infected by SARS-CoV-2 from Wuhan, China and tracked the presence of anti-SARS-CoV-2 antibodies in the patients for more than 12 months. We found the duration (days) of anti-SARS-CoV-2 IgG in the patients was significant longer in chemotherapy (mean: 175; range: 75 to 315) and radiotherapy groups (mean: 168; range: 85 to 265) than in non-chemo- or radio-therapy group (mean: 58; range: 21 to 123) after their recovery from COVID-19. We also used single-cell RNA sequencing to track the immunologic changes in a representative patient recovered from COVID-19 and found that CD8 + effective T cells, memory B cells and plasma cells were persistently activated in the patient undergoing chemotherapy. Together, our findings show that chemotherapy and radiotherapy might be beneficial to extend the duration of anti-SARS-CoV-2 IgG.
format	article
author	Yongsheng Huang Jing Yu Dan Li Kai He Wenyang Liu Lin Wang Yeshan Chen Conghua Xie Xiaowei Wu
author_facet	Yongsheng Huang Jing Yu Dan Li Kai He Wenyang Liu Lin Wang Yeshan Chen Conghua Xie Xiaowei Wu
author_sort	Yongsheng Huang
title	Durable tracking anti-SARS-CoV-2 antibodies in cancer patients recovered from COVID-19
title_short	Durable tracking anti-SARS-CoV-2 antibodies in cancer patients recovered from COVID-19
title_full	Durable tracking anti-SARS-CoV-2 antibodies in cancer patients recovered from COVID-19
title_fullStr	Durable tracking anti-SARS-CoV-2 antibodies in cancer patients recovered from COVID-19
title_full_unstemmed	Durable tracking anti-SARS-CoV-2 antibodies in cancer patients recovered from COVID-19
title_sort	durable tracking anti-sars-cov-2 antibodies in cancer patients recovered from covid-19
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/2bf4547a9fc44aaab5e7dcaaaeccfa1a
work_keys_str_mv	AT yongshenghuang durabletrackingantisarscov2antibodiesincancerpatientsrecoveredfromcovid19 AT jingyu durabletrackingantisarscov2antibodiesincancerpatientsrecoveredfromcovid19 AT danli durabletrackingantisarscov2antibodiesincancerpatientsrecoveredfromcovid19 AT kaihe durabletrackingantisarscov2antibodiesincancerpatientsrecoveredfromcovid19 AT wenyangliu durabletrackingantisarscov2antibodiesincancerpatientsrecoveredfromcovid19 AT linwang durabletrackingantisarscov2antibodiesincancerpatientsrecoveredfromcovid19 AT yeshanchen durabletrackingantisarscov2antibodiesincancerpatientsrecoveredfromcovid19 AT conghuaxie durabletrackingantisarscov2antibodiesincancerpatientsrecoveredfromcovid19 AT xiaoweiwu durabletrackingantisarscov2antibodiesincancerpatientsrecoveredfromcovid19
_version_	1718387134739513344

Durable tracking anti-SARS-CoV-2 antibodies in cancer patients recovered from COVID-19

Ejemplares similares